Jonathan Grossman
Neurology · Valparaiso, INNPI 1093210114
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 25.2% of the total. 2025 is the largest year on record at $1,964, more than ten times the $15 reported in 2019. That places this record below the midpoint for neurology clinicians in IN, where the typical reported total is $1,614.
Across 118 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$555
- Pfizer$143
- EMD Serono, Inc.$139
- Sanofi$128
- Lilly USA, LLC$106
- Argenx US, Inc.$95
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,205100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 42 | $555 |
| Pfizer | 13 | $143 |
| EMD Serono, Inc. | 7 | $139 |
| Sanofi | 2 | $128 |
| Lilly USA, LLC | 5 | $106 |
| Argenx US, Inc. | 4 | $95 |
| Novartis | 4 | $94 |
| Acadia Pharmaceuticals Inc | 4 | $89 |
| Jazz Pharmaceuticals Inc. | 2 | $65 |
| UCB, Inc. | 2 | $64 |
| Inspire Medical Systems, Inc. | 2 | $57 |
| Genentech USA, Inc. | 2 | $54 |
| TG Therapeutics, Inc. | 2 | $53 |
| Aucta Pharmaceuticals, Inc. | 2 | $50 |
| Tanabe Pharma America, Inc. | 2 | $46 |
| Amneal Pharmaceuticals LLC | 2 | $40 |
| Neurocrine Biosciences, Inc. | 2 | $38 |
| Neurelis, Inc. | 2 | $37 |
| Eisai Inc. | 2 | $36 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| AstraZeneca | 1 | $31 |
| SK Life Science, Inc. | 1 | $27 |
| Lundbeck LLC | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $23 |
| Abbott | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Merz Pharmaceuticals, LLC | 1 | $17 |
| Philips North America LLC | 1 | $15 |
| CSL Behring | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$2,205 in reported general payments places this provider in the 50th percentile of 308 neurology providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 15 | $238 |
Paid to pharmacies, not to this prescriber.
Other neurology in Valparaiso
- Mahmood AlnahassValparaiso$21K
- William ConteMerrillville$1.2M
- Anthony SimchakLafayette$720K
- Mark JanickiLebanon$573K
- Ajay GuptaFort Wayne$411K
- Roderick WarrenEvansville$296K
- Ender AkanMunster$296K
- Christopher WilsonAvon$283K
- Marlene BultemeyerFort Wayne$277K
- Jerry SmarttCarmel$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.